Development of a protease-resistant reporter to quantify BCR–ABL activity in intact cells. Issue 21 (16th September 2016)

• Record Type: Journal Article
• Authors: Proctor, Angela; Zigoneanu, Imola G.; Wang, Qunzhao; Sims, Christopher E.; Lawrence, David S.; Allbritton, Nancy L.
• Is Part Of: Analyst. Volume 141:Issue 21(2016)
• Page Start: 6008
• Page End: 6017
• Publication Date: 2016-09-16
• Subjects: Chemistry, Analytic -- Periodicals; 543
• DOI: 10.1039/c6an01378c
• Languages: English
• ISSNs: 0003-2654

Abstract

Abstract : A peptidase-resistant ABL kinase substrate was developed by identifying protease-susceptible bonds on an ABL substrate peptide and replacing flanking amino acids with non-native amino acids. Abstract : A peptidase-resistant ABL kinase substrate was developed by identifying protease-susceptible bonds on an ABL substrate peptide and replacing flanking amino acids with non-native amino acids. After an iterative design process, the lead, or designed, peptide X-A possesses a six-fold longer life in a cytosolic lysate than that of the starting peptide. The catalytic efficiency ( k cat / K M ) of purified ABL kinase for the lead peptide (125 s −1 μM −1 ) is similar to that of the starting peptide (103 s −1 μM −1 ) demonstrating preservation of the peptide's ability to serve as a kinase substrate. When incubated in cytosolic lysates, the lead peptide is slowly degraded into 4 fragments over time. In contrast, when loaded into intact cells, the peptide is metabolized into 5 fragments, with only 2 of the fragments corresponding to those in the lysate. Thus the two environments possess differing peptidase activities, which must be accounted for when designing peptidase-resistant peptides. In both settings, the substrate is phosphorylated by BCR–ABL providing a readout of BCR–ABL activity. A small panel of tyrosine kinase inhibitors verified the substrate's specificity for BCR–ABL/ABL kinase activity in both lysates and cells in spite of the multitude of other kinases present. The designed peptide X-A acts as a long-lived BCR–ABL kinase reporter in the leukemic cells possessing the BCR–ABL mutation.